Battisti et al. [68] showed that serum BCHE levels decreased progressively in prostate cancer, and even more in patients with bone metastases, compared to control groups, and moreover, these decreased BCHE levels correlated with decreased biochemical recurrence-free survival [69]. Here, BCHE is linked to prostate carcinoma.